Role of Ganoderma lucidum against triazole drugs resistant Aspergillus species

Abstract

Edible Medicinal mushroom Ganoderma lucidum have an established in use of traditional new antimicrobial drugs and oriental therapies. The current study helps to describe the development of acquired resistance and efficacy of certain antifungal agents against different Aspergillus species. A total of 150 clinical isolates of different Aspergillus spp. were obtained from tertiary care center, Puducherry. Various drug concentrations (Posaconazole, Voriconazole, Itraconazole and Ganoderma extract) are based on the measurement of the fungal growth in the presence, so as to determine the minimum inhibitory concentration (MIC) of antifungals was performed according to the CLSI guidelines. Ganoderma lucidum full part fruiting body were collected and prepared extraction with help of ethanol at various concentrations
0.008 to 8 μg/ml. Triazoles and Ganoderma extract of MIC distribution among different Aspergillus species were as follows: A. fumigatus - Ganoderma extract, 0.12; itraconazole, 1; posaconazole, 0.25; voriconazole, 0.5; A. flavus - Ganoderma extract, 0.25; itraconazole, 1; posaconazole, 0.25; voriconazole, 0.5; A. niger - Ganoderma extract, 0.12; itraconazole, 1; posaconazole, 0.5; voriconazole, 1; and A. terreus - Ganoderma extract, 0.25; itraconazole, 1; posaconazole, 0.25; and voriconazole, 0.5. Ganoderma extract, posaconazole, voriconazole, and itraconazole. Majority of Aspergillus species exhibited in vitro resistance to voriconazole followed by itraconazole.